DECREASE III: Beta-blocker use to lower operative mortality in high-risk vascular surgery


The DECREASE III study, which took place in The Netherlands between June 2004 and April 2008, showed that patients treated with fluvastatin (Lescol, Novartis) showed an improved cardiac outcome after surgery.

The results from the study were presented by Professor Don Poldermans, Erasmus MC Rotterdam, The Netherlands, at the European Society of Cardiology (ESC) meeting, held in Munich, in September.

Annually, approximately 40 million people undergo noncardiac surgery in the EU. Of these patients approximately 400,000 (1%) will suffer a perioperative myocardial infarction (PMI) while approximately 133,000 (0.3%) die because of cardiac complications. In particular in patients undergoing noncardiac vascular surgery the incidence of perioperative cardiac complications is high with cardiac mortality rates exceeding 2%. Indeed perioperative cardiac events are the major cause of adverse outcome in vascular surgery patients.

Poldermans stated that the pathophysiology of a PMI is complex. “While cardiac oxygen demand/supply mismatch in patients with coronary artery disease might be counteracted by appropriate beta-blocker use or coronary revascularisation in these patients, coronary plaque instability leading to plaque rupture and thrombosis remains a significant problem,” he said. Recent retrospective studies suggested a potential beneficial role of statins in the prevention of PMI, in particular by “stabilising” coronary plaques due to their pleiotropic, anti-inflammatory effects. Therefore, Poldermans explained, the aim of the randomised, double blind, Dutch Echographic Cardiac Risk Evaluation Applying Stress Echo (DECREASE) III trial was to assess the cardioprotective effect of fluvastatin XL on top of beta-blocker therapy in vascular surgery patients.


Study design

Between June 2004 and April 2008, 497 statin-naive patients scheduled for vascular surgery were included in the trial at Erasmus MC Rotterdam, The Netherlands. Patients were randomised to receive either placebo or fluvastatin extended release at a dose of 80mg once daily. Treatment was started at the outpatient clinic on the day of randomisation, median 37 days prior to the surgical procedure and was continued at least during the first 30 days after surgery.

Inflammatory markers at baseline, including hs-CRP and IL-6 were assessed in patients allocated to fluvastatin or placebo. At hospital, admission levels of hs-CRP and IL-6 were significantly lower in patients on fluvastatin (respectively 6mg/L vs. 4.66mg/L, p=.030 and 8.45pg/mL vs 5.75pg/mL, p=.024).

The primary analysis was intention-to-treat and involved all patients who were randomly assigned to either fluvastatin or placebo. Directly after surgery, study treatment was temporarily discontinued in 115 (23%) patients for a median duration of two days because of the inability to take the study drug orally. A total of 34 patients discontinued study medication because of laboratory abnormalities; 16 (3.2%) because of alanine aminotransferase (ALAT) exceeding three times the upper limit of normal, 13 (2.6%) because of creatine kinase (CK) exceeding ten times the upper limit of normal, and 5 (1%) because of a combination of elevated ALAT and CK.


Primary and secondary endpoints

Myocardial ischaemia was detected in 74 (14.9%) patients within 30 days of the initial vascular surgical procedure. A total of 27/250 (10.9%) patients allocated to fluvastatin reached the primary endpoint compared to 47/247 (18.9%) patients allocated to placebo treatment (OR .53; 95% CI .32–.88). Hence, the number needed to treat (NNT) to prevent one patient experiencing myocardial ischaemia was 12.5 patients.

A total of 18 (3.6%) patients died within 30 days after surgery, of which 12 (2.4%) were attributable to cardiovascular causes. Additionally, 25 (5%) patients experienced a nonfatal myocardial infarction within 30 days after surgery. The combined endpoint of cardiovascular death and nonfatal myocardial infarction was reached in 37/497 (7.4%) patients. A total of 12/250 (4.8%) patients allocated to fluvastatin therapy reached the combined endpoint, compared to 25/247 (10.1%) allocated to placebo. Hence, fluvastatin therapy was associated with a 52% relative reduction in the incidence of cardiovascular death or myocardial infarction (OR .48; 95% CI .24–.95). The NNT for the composite endpoint of cardiovascular death or nonfatal myocardial infarction is 18.9 patients.


Adverse events

The proportion of patients experiencing any adverse event was similar between the fluvastatin and placebo groups. The proportion of patients experiencing a CK rise of more than ten times the upper limit of normal was 4.1% in the fluvastatin group and 3% in the placebo group. The median peak CK level was 141U/L in patients on fluvastatin and 113U/L in patients on placebo (p=.24). The proportion of patients with significant increase in ALAT levels, i.e. more than three times the upper limit of normal, was 3.1% in the fluvastatin group and 5.2% in the placebo group. The median peak ALAT level was 23U/L in patients on fluvastatin and 24U/L in patients on placebo.

The researchers concluded that fluvastatin XL therapy was associated with improved postoperative cardiac outcome in high-risk patients undergoing elective vascular surgery.